ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
RAST+: pre-positivity application of EUCAST RAST using BACTEC FX growth detection plots - a proof-of-concept study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely antimicrobial susceptibility testing (AST) from blood cultures is crucial to optimize antimicrobial therapy. PURPOSE: The aim of this study is to accelerate AST results by applying EUCAST RAST method before blood culture positivity (RAST+) by utilizing Growth and Detection Plots (GDPs) generated by the BD BACTEC FX (Becton Dickinson, Sparks, MD, USA) system.
methodsQuality control strains and 20 clinical isolates were inoculated into BACTEC™ Plus Aerobic bottles and incubated in the BD BACTEC FX system. GDPs were continuously monitored to detect the steeping phase indicative of early bacterial growth prior to signal positivity. Bottles were removed at the beginning of the steeping phase and RAST+ was performed using 300 µL inoculum. Zone diameters were interpreted according to EUCAST RAST guidelines.
resultsThe RAST+ method yielded inhibition zones within acceptable ranges both for 150 µL and 300 µL inocula for quality control strains, with improved readability at 300 µL. Of 185 antibiotic disks tested, 159 (85.9%) produced interpretable results by using a 300 µL inoculum. When compared to the reference method, RAST+ achieved a categorical agreement of 96.2%. The rates of very major, major, and minor errors were each 1.3%, indicating a high level of concordance and diagnostic reliability.
conclusionsTo the best of our knowledge, this is the first study to analyze GDPs in order to predict blood culture positivity. Furthermore, it is also the first to apply rapid AST directly from blood culture bottles (RAST) before the positivity signal appears. RAST+ is a proof-of-concept approach for detecting bacterial growth and performing antimicrobial susceptibility testing directly from blood cultures before they signal positive, potentially reducing turnaround times (TAT) and supporting earlier clinical decision-making.
Indexed as
Identifiers
42234382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.